twitter:title

The mission of SOTIO, the biotechnology company, is to research, develop and open up access to new innovative treatment methods for patients suffering from ...

description

twitter:description

https://www.datocms-assets.com/40359/1618564444-dsc0532.jpg?auto=format&fit=max&w=1200

twitter:image

twitter:image:alt

twitter:card

twitter:site

Sotio

www.sotio.com

SOTIO Biotech a.s.

Sotio Biotech B.V. 

PPF Biotech B.V.

SOTIO, part of PPF Group since 2012, coordinates the Group&rsquo;s biotechnology activities. It is building a diversified portfolio of immuno-oncology programmes based on in-house research and development, partnerships, licensing agreements, investments, mergers, and acquisitions. It has operations in Europe and the US, with principal centres in Prague, Basel, and Boston. SOTIO Group, which has its own scientific and laboratory facilities in Prague, is the largest privately funded research endeavour in the Czech Republic.

SOTIO&rsquo;s research and development programmes embrace next-generation antibody-drug conjugate (ADC) oncology products, personalised cellular immunotherapy on the CAR-T platform, and IL&ndash;15 superagonist-based treatments, including immunocytokines.&nbsp;
SOTIO has been validating the safety and efficacy of its products in comprehensive clinical trials conducted in Europe and the US since 2012.&nbsp;&nbsp;
In July 2024, SOTIO entered into a multi-target antibody agreement with Biocytogen. This option and licence agreement includes multiple fully human bispecific antibodies developed using with Biocytogen&rsquo;s proprietary platform. The agreement enables SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs.

Other PPF Biotech Holdings

Sotio Biotech

Czech Republic

Switzerland

France

SOTIO Biotech Group, operating within the&nbsp;PPF Biotech arm, researches and develops&nbsp;innovative cancer treatments and applies its&nbsp;scientific immunotherapy knowledge to clinical&nbsp;trials. Teams of leading experts from all over&nbsp;the world work for SOTIO as part of its extensive&nbsp;international activities.&nbsp;

Radek Špíšek

"SOTIO exemplifies the world-class standard of Czech science in its mission and results. Our efforts are focused on finding a cure for cancer."

Under the Terms of Use of these websites, it is forbidden to use the photographs contained in the Annual Reports posted on the aforementioned websites for any purposes other than for exclusively personal and non-commercial use, to copy, reproduce, edit, modify, rearrange or otherwise tamper with the photographs contained in the Annual Reports, or to disseminate any such photographs treated in this way. You may display the content of the Annual Reports, including photographs, on a&nbsp;computer, tablet, or mobile telephone screen, print individual pages on paper (but not photocopy them), and store such pages in electronic form on a&nbsp;disk or on your mobile telephone (but not on any server or other networked storage device) for your personal, non-commercial use only.

Annual Reports Agreement

PPF a.s., with its registered office in Prague 6, Evropsk&aacute; 2690/17, postal code 16041, Czech Republic, entered in the Commercial Register kept by the Municipal Court in Prague, Section B, Insert 4495, IČ: 25099345 (hereinafter referred to as the &ldquo;PPF Company&rdquo;), offers download on the website <a href="//www.ppf.eu">www.ppf.eu</a> (hereinafter referred to as the "website") official photos that are intended for download by PPF (such photos hereinafter referred to as "Photos").
Photographs, as well as all other material placed on any part of the website (including text, website design, graphics, all images on this website, as well as the selection and arrangement of files contained on this website) - hereinafter "content", are subject to protection pursuant to Act No. 121/2000 Coll., on Copyright, on Rights Related to Copyright and on Amendments to Certain Acts (Copyright Act), as amended (hereinafter referred to as the &ldquo;Copyright Act&rdquo;). Only PPF is entitled to exercise proprietary copyrights to the Photos and content, as well as to the website.
If you are interested in downloading and using some of the Photos, you must always accept the license agreements listed below. It is expressly stated that you acknowledge that you are not authorized to download and use any Photograph without accepting these license agreements.
License Agreement
The photo is provided for download and use under the conditions set forth in these license agreements. PPF grants you the right to download and use the Photo only if you unconditionally accept the license agreement set forth in this section. Unless otherwise agreed between you and PPF, any use of the Photograph that is not in accordance with these license agreements is prohibited.
By accepting these license agreements, you acquire a free, non-exclusive, non-transferable, territorially and time-limited license to download and view the Photos on your computer, tablet or mobile phone and print them on paper (but not to make copies). Unless otherwise stated or agreed below, you are entitled to use the Photos only for your own personal purposes.
Unless otherwise stated or agreed below, it is excluded and prohibited to copy (make copies), reproduce, modify, change, transform or otherwise interfere with the Photographs and further reproduce the Photographs concerned. Furthermore, it is forbidden to hand over, sell or otherwise provide the Photographs for use to another person (including the granting of a license or sublicense) or to make the Photographs available to another person in any way.
You further exclude and by accepting these license agreements you agree not to:
<ul>
 <li>Use the photographs in such a way that the persons depicted can give the public the impression that they support or promote political, religious, economic or other ideological movements, parties and other groups or political, religious, economic or other currents of thought (including and their display on promotional materials, including billboards);</li>
 <li>Use and edit photographs in such a way that the persons shown on them may give the public the impression that they are promoting erotic or sexual services, sexual health products or the promotion of sexual desire and libido;</li>
 <li>Use and edit the photographs so that the persons depicted on them may give the public the impression that the persons depicted on them promote drugs, alcohol (of any kind) and / or cigarettes;</li>
 <li>Use photographs for advertising purposes of any kind;</li>
 <li>Use photographs for the purpose of publication on billboards;</li>
 <li>Take photos by placing them on gift items;</li>
 <li>Use photographs as part of business communications;</li>
 <li>Use the photographs in such a way that the persons depicted on them may give the public the impression that those persons purchase, use or promote any goods or services;</li>
 <li>Use the Photographs in a manner that may give rise to reasonable doubt that such use could infringe or otherwise disparage the personal rights of the persons depicted in the Photographs.</li>
</ul>
If you have any doubts as to whether you are entitled to use the Photograph, taking into account the restriction mentioned above under the last indent, you undertake to seek the opinion of PPF before using the Photograph itself.
If you are interested in using the Photograph in a manner or to the extent beyond the scope of these license agreements, please contact PPF, specifically contact PPF at the e-mail address <a href="mailto:images@ppf.cz">images@ppf.cz</a>. In the e-mail message, state which Photo, for what purpose, to what extent, in what way and for how long you are interested in using it. With regard to the purpose, scope and manner of use of the Photograph that you specify in your application, it will be at PPF's sole discretion whether your application will be approved or rejected and you will be able to use the Photograph. In order to obtain consent to the use of the Photograph, you are obliged to provide only true and complete data in the application. If your application is approved, you will be able to download the requested Photo and use it for the purpose, manner and to the extent specified in the application. However, PPF reserves the right to set the conditions for the scope and method of use Photography.
By downloading the Photo, you do not become its owner in any way. The User who has been allowed to download the Photo undertakes to use the Photo only in accordance with the purpose and to the extent to which the Photo has been allowed to download and use, and only once.
For the media
Notwithstanding the above license agreements, media representatives are entitled, based on the acceptance of these license agreements, to use the Photographs under a news license and in an editorial sense, ie primarily as part of an article in newspapers, magazines and newspaper and magazine websites, including for commercial purposes. In the cases described in this paragraph, you may modify the Photo only by common technical interventions that do not change the image content of the Photo, which means cropping the Photo, and common color adjustments that do not change the meaning or image meaning of the Photo. With the exception of the above, the restrictions on the use of the Photograph resulting from the license agreements also apply to media representatives and the media itself.
General provisions
In the event that you request to combine the Photograph with the author's work (literary or artistic), you are obliged to ask PPF for consent to combine the Photograph with the author's work by sending a request to the e-mail address images@ppf.cz. PPF reserves the right, prior to the actual issuance of the consent, to request from you the submission of such copyright work for approval and as a basis for the decision to issue such consent. PPF also reserves the right not to issue a consent to the merger of the Photograph and the author's work after the assessment of the author's work. PPF also reserves the right to request the submission of a graphic design of each material on which the Photograph is to be displayed.
If you wish to use the Photograph on behalf of your employer, you represent and agree that you are authorized to accept these license agreements on behalf of your employer.
Only PPF is entitled to change or supplement these license agreements. The legal relations that arose between PPF and the user of Fotografie before the change or cancellation of these license agreements are governed by the wording effective as of the date of these relations.
These license agreements are governed by the applicable laws of the Czech Republic. All disputes arising in connection with the use of the Photograph will be heard by a locally competent court in the Czech Republic in accordance with the laws of the Czech Republic.
These license agreements are valid and effective on the date of their publication. These license agreements were published on 17/6/2021.
These license agreements are also prepared in English and Czech. In the event of a conflict between the Czech and English texts of the license agreements, the Czech text of the license agreements shall apply.

Terms of use of website content

Developing a biotech company in Central Europe is an extremely bold move, says Sotio CEO

PPF Group is an international investment group founded in the Czech 
Republic in 1991. It has grown to manage operations in 25 countries around the world.

https://www.datocms-assets.com/40359/1609949272-ppf-gate-web.jpg?auto=format&fit=max&w=1200

You&rsquo;re on a&nbsp;lengthy quest to tackle one of humanity&rsquo;s greatest problems, cancer. How far are you from your goal, in whatever form it takes? When it comes to developing new drugs, once you&rsquo;ve discovered a&nbsp;promising substance in the lab, it takes eight to twelve years to go through all the phases of clinical trials before it can be brought to market. We are currently running three such programmes, three substances, where we have transitioned from the laboratory to clinical trials. For all of them, we&rsquo;re now somewhere around the stage where we should know by the&nbsp; end of this year whether the data is promising and whether it warrants proceeding to the final step in the trial, which is the registrational study or phase&nbsp;three&nbsp;clinical trial. That is the final step, and if it goes well, it means we will have a&nbsp;drug that can be marketed.
Can you quantify the likelihood of that scenario unfolding? We should know by the end of the year, and we&rsquo;ll have an answer for all three substances by the middle of next year. If they successfully pass the second phase of clinical trials, there is a&nbsp;30 to 40 percent chance they&rsquo;ll be marketed. It&rsquo;s early days yet, so I&nbsp;would estimate our likelihood of success to be somewhere around 20 percent at the moment. Right at the start of the research, it was well below one percent.
During our interview Ms.&nbsp;Kellner&rsquo;s assistant called you for an appointment. This leads me to asking how Sotio&rsquo;s role has changed in the group since Mr.&nbsp;Kellner&rsquo;s death? It&rsquo;s hard to say right now, because the whole group has been going through changes since Mr. &Scaron;mejc came on board. But we clearly have the backing of both the family and PPF&rsquo;s management for the Sotio project to move forward. Mr. Kellner was very enthusiastic about Sotio, it was very close to his heart. He joined meetings that went into quite a&nbsp;bit of detail and enjoyed it. It&rsquo;s very hard for anyone to catch up quickly with the ten years he spent keenly interested in it. Mr.&nbsp;&Scaron;mejc and the Kellner family do have the drive to understand the issues at play, but it will take two years for them to get there. I&rsquo;m now referring to the complexity of our work and the business landscape we&rsquo;re competing in. Cancer research is hugely competitive. And the fact that we&rsquo;re a Czech&nbsp;company trying to compete with Western and American biotechnology companies is both bold and complicated.
And frankly, is it worth it? Take the US biotech sector &ndash; surely they&rsquo;re bursting at the seams and perhaps they&rsquo;re working on exactly the same thing? And this isn&rsquo;t even mentioning Asia. Yes, it&rsquo;s worth it, but it&rsquo;s obviously a&nbsp;challenge. The talent, expertise, and professional and business experience are concentrated on the west and east coasts of the United States. Then there&rsquo;s a bit in Western Europe, but they&rsquo;re the poor relatives. And then we have a&nbsp;few rare birds in Central Europe. We&rsquo;re very conscious of that. There&rsquo;s a&nbsp;lot of competition, and the last two years have not been kind to the biotech industry because of the economic crisis and there isn&rsquo;t much appetite to invest in something so risky. Smaller companies are used to raising money every two years so they can proceed to the next phase of clinical trials, but they&rsquo;re not having much success right now. Investment in biotech has tanked over the last two years, being very muted. But because we&rsquo;re backed by a dependable investor, we have the advantage of not having to stall any of our projects.
Mr. Kellner had a&nbsp;soft spot for Sotio. Can we expect the new PPF management to be more pragmatic &ndash; is there any risk that the limits will be reined in? We haven&rsquo;t sensed that, but there has definitely been some change, which I&rsquo;m glad to see. As you progress with a&nbsp;biotech project, the rule of thumb is that each successive phase is a lot more expensive than the one before it. And it&rsquo;s very common in this business that at some stage of clinical development, big pharmaceutical companies step in, looking for promising substances that biotech companies might have. Conversely, another typical scenario is that at some stage of product development, a&nbsp;biotech company tries to find a&nbsp;solid partner, either to buy the project or to be involved in its ongoing development.
Is that where you are headed right now? Yes, we&rsquo;re more open to collaboration with partners. If we see our programmes yielding promising data, instead of resisting, we actively approach pharmaceutical companies and present our results to them. A&nbsp;pharmaceutical company could shoulder some of the costs and provide important know-how. In this respect, Mr. &Scaron;mejc has a&nbsp;different, much more rational approach. Mr. Kellner liked to be completely in charge, so the vast majority of companies in PPF&rsquo;s portfolio were fully controlled by the group. But when it comes to projects as risky as biotechnology, partnerships make a&nbsp;lot of sense.
So an investor could enter Sotio by acquiring part of the company? There are various scenarios, one being that a&nbsp;biotech-focused investment fund might come along and take a&nbsp;shine to our portfolio.
So how much of Sotio is up for sale? It&rsquo;s impossible to say. These interactions do crop up from time to time, but the market is stacked against us, the timing isn&rsquo;t quite right. So even if this were perhaps our preferred route, which it&rsquo;s not entirely, the market climate wouldn&rsquo;t allow it.
But you&rsquo;re holding some valuable cards now &ndash; a&nbsp;20% chance of launching a&nbsp;drug is a&nbsp;lot. Yes, but don&rsquo;t forget that in the last five years there were around 120 biotech IPOs on the Nasdaq exchange. Last year, there were just four. The market is in stasis. Everyone is waiting for the economy to pick up and for funds to whet their investment appetite again. A&nbsp;more appealing scenario for us would be a&nbsp;partnership with a&nbsp;pharmaceutical company, with one of the programmes being licensed.
Have there been any negotiations? Discussions are ongoing, but I&nbsp;can&rsquo;t comment on them. I can say that once a programme gets to the clinical phase and we feel that the data looks good, we can then make the pitch to potential partners.
One of your substances going through&nbsp;research has potentially reached a commercial milestone. How big a&nbsp;step forward is that? The &ldquo;nanrilkefusp alfa&rdquo; programme, formerly known as SOT101, has successfully passed the first phase of clinical development. The second phase involves testing on a&nbsp;sample of around 300 people and monitoring both safety and incipient signs of efficacy. If it goes well and we see progress in perhaps a&nbsp;third of the patients, a&nbsp;large, very expensive study involving hundreds, perhaps even&nbsp;thousands of patients will be done. That study will investigate whether the substance statistically increases the odds of survival. And the milestone is that with SOT101, we&rsquo;ve now gone past phase one&nbsp;and we&rsquo;re clearly seeing patients who have benefited from it. We&rsquo;re now running three phase two&nbsp;trials. The real milestone will be when we see which substances it makes sense to start the ultra-expensive phase three&nbsp;with.
How much would that phase cost? It costs somewhere between fifty and a&nbsp;hundred million dollars, and that&rsquo;s for each substance separately. But the cost of each substance may differ somewhat.
Is PPF prepared to finance it? That remains to be seen. It depends on the data when we get to evaluating phase two. Personally, I&nbsp;would us to go down the route of partnering with a&nbsp;big pharmaceutical company. It would elevate us to a&nbsp;whole other level of quality. Coming out of Central Europe, we would suddenly be on the radar in the US biotech world. I&nbsp;would always be in favour of us going down that road when we reach those expensive phases. If the data from the clinical trials looks good, each of these substances could be the subject of a&nbsp;multi-billion-dollar deal with large corporations.
If the second phase doesn&rsquo;t work for any of these substances, will you call it a&nbsp;day? It&rsquo;s yet to be seen. I&nbsp;honestly don&rsquo;t know. We have three programmes in clinical trials, but there are others in the lab research phase. Sotio&rsquo;s vision is to focus on what we&rsquo;re best at, which is researching and putting new molecules through clinical trials. If the big three don&rsquo;t make it, there are still so-called preclinical programmes in the pipeline that we would continue to work on. And here we&rsquo;re talking about much lower costs, somewhere in the order of millions of dollars.
If you were to actually bring the research to a&nbsp;successful conclusion in phase three, does that mean you&rsquo;d have a&nbsp;drug ready to package? Yes, if it goes through, there will be some sort of marketing authorization process, but that&rsquo;s just an administrative step. Then it really is ready to package up. But after that, there&rsquo;s the extremely difficult stage of marketing and commercialising the product amid the enormous competition that is out there now.
And would the box say Sotio on it? If it was developed by Sotio itself and we were the ones who did the third phase, it would say Sotio. And that means Sotio would become a&nbsp;pharmaceutical company.
Is that the holy grail of your business? It&rsquo;s kind of the ultimate, but perhaps rather naive, vision.&nbsp;But discussions about Sotio&rsquo;s strategic goals are still ongoing.
How crucial and business-relevant would it be to have three available drugs on your desk? The bottom line is that each drug has patent protection, and when that patent expires, the drug can be produced generically, but the margin on them is lost. So big companies are pushed to keep adding new, innovative drugs to their pipeline that have good results but also patent protection. That&rsquo;s why they&rsquo;re willing to pay to make products which look promising, if they can see that the data makes sense to us and that there is a good chance it will work. You&rsquo;ll find similar transactions in the order of billions of dollars for every product in the last five years. The business potential might then emerge after successfully passing phase two.
I didn&rsquo;t look at the income statement, even though it&rsquo;s not really relevant in biotech. There was a loss of 330 million for 2021. What was it last year? Those are accounting numbers and say nothing about reality. The annual budget is tens of millions of euros, and it shows that it&rsquo;s just a big and expensive business. When you get to the clinical trial phase, the costs mainly reflect the number of people involved. Each patient represents a significant cost, which can be somewhere in the order of hundreds of thousands of dollars.
Is it fair to say that this year is a major milestone that will seal Sotio&rsquo;s fate? Yes, it&rsquo;s an important time for the company&rsquo;s future and what happens next for Sotio. Phase one of BOXR1030 and SOT102 will end, and phase two data will be crucial for SOT101. Some pharmaceutical companies in the past invested in substances before or during phase one. Given the market situation, most deals are now done after phase two, where there need to be clear signals on the product&rsquo;s efficacy. Generally in our industry, the decisions being made now involve much less risk than in the past. The market environment is the worst it has been in the 12 years I&rsquo;ve worked here, and it&rsquo;s worse than after the collapse of Lehman Brothers.
author:&nbsp;Jaroslav Bukovsk&yacute; source: https://www.e15.cz/rozhovory/rozvijet-ve-stredni-evrope-biotechnologickou-firmu-je-nesmirne-troufale-rika-sef-sotia-1396413?openpremium=16e873b7fa63de8f054be7840d462987

Sotio Biotech

Other PPF Biotech Holdings

Autolus Therapeutics

Cellestia Biotech

"SOTIO exemplifies the world-class standard of Czech science in its mission and results. Our efforts are focused on finding a cure for cancer."

Radek Špíšek

Contacts

SOTIO Biotech a.s.

Sotio Biotech B.V.

PPF Biotech B.V.

Related

Autolus Therapeutics Autolus Therapeutics is a leader in the development of treatments based on CAR-T cells (genetically engineered T cells). The company is dedicated to the clinical development of a wide portfolio of next-generation T-cell therapies targeting both hematological and solid tumors. www.autolus.com
Cellestia Biotech Cellestia Biotech was founded in 2014 as a spin-off of the Swiss Federal Institute of Technology Lausanne (EPLF). Cellestia’s lead development compound is CB-103, a novel, first-in-class oral pan-NOTCH inhibitor with an innovative mode of action meant for the treatment of patients with NOTCH-driven lymphomas and solid tumors. www.cellestia.com